News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Symphogen A/S to Present Rozrolimupab (SYM001) Final Data at 2011 American Society of Hematology Meeting



12/6/2011 6:31:19 AM

COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen announced today that Phase 2 final data will be presented from an open-label, multi-center clinical trial evaluating the efficacy, safety, and tolerability of Rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune Thrombocytopenia (ITP) at the 53rd Annual Meeting of the American Society of Hematology (ASH) (http://www.hematology.org/Meetings/Annual-Meeting/) in San Diego, CA, US on December 12, 2011 from 3:45 to 4:00 PM. Final results will be presented in an oral session: “Disorders of Platelet Number or Function” with the title “Final results From a Phase II Trial with the First-in-Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia (ITP)” by professor Tadeusz Robak of University of Lodz, Poland.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES